| Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy GP Takacs, JA Flores-Toro, JK Harrison Pharmacology & therapeutics 222, 107790, 2021 | 34 | 2021 |
| Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner GP Takacs, CJ Kreiger, D Luo, G Tian, JS Garcia, LP Deleyrolle, ... Frontiers in Immunology 13, 993444, 2023 | 15 | 2023 |
| Functional dependency analysis identifies potential druggable targets in acute myeloid leukemia Y Zhou, GP Takacs, JK Lamba, C Vulpe, CR Cogle Cancers 12 (12), 3710, 2020 | 8 | 2020 |
| Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+ myeloid cells into the tumor microenvironment in a redundant manner GP Takacs, CJ Kreiger, D Luo, G Tian, JS Garcia, LP Deleyrolle, ... bioRxiv, 2022.07. 08.499173, 2022 | 2 | 2022 |
| CRISPR Dropout Screens Identify DHODH,PIK3C3, and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia G Takacs, Y Zhou, DJ King, A Meacham, L Alex, A Tagmount, A Sobh, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 2 | 2019 |
| Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma HG Anderson, GP Takacs, DC Harris, Y Kuang, JK Harrison, TL Stepien Journal of Mathematical Biology 88 (1), 10, 2024 | 1 | 2024 |
| TMIC-32. TUMOR CELL CILIA ASSOCIATE WITH SPECIFIC IMMUNE CELL POPULATIONS IN HUMAN AND MOUSE MODELS OF GBM L Deleyrolle, J Harrison, G Takacs, M Sarkisian Neuro-Oncology 24 (Supplement_7), vii278-vii278, 2022 | 1 | 2022 |
| Method to identify silent codon mutations that may alter peptide elongation kinetics and co-translational protein folding R Worthington, E Ball, B Wolf, G Takacs Proteomics for Drug Discovery: Methods and Protocols, 237-243, 2017 | 1 | 2017 |
| Glioma-derived M-CSF and IL-34 license M-MDSCs to suppress CD8+ T cells in a NOS-dependent manner GP Takacs, JS Garcia, CA Hodges, CJ Kreiger, A Sherman, JK Harrison bioRxiv, 2024.06. 05.597474, 2024 | | 2024 |
| Optimal control of combination immunotherapy in a glioblastoma-immune dynamics model HG Anderson, GP Takacs, JK Harrison, L Rong, TL Stepien bioRxiv, 2024.04. 29.591725, 2024 | | 2024 |
| DR5 disulfide bonding as a sensor and effector of protein folding stress ME Law, ZM Dulloo, SR Eggleston, GP Takacs, GM Alexandrow, M Wang, ... bioRxiv, 2024.03. 04.583390, 2024 | | 2024 |
| Systemically targeting monocytic MDSCs using dendrimers and their cell-level biodistribution kinetics CA Littrell, GP Takacs, C Siva Sankara, A Sherman, KA Rubach, ... bioRxiv, 2024.02. 14.580395, 2024 | | 2024 |
| CD4 T CELLS MEDIATED UPREGULATION OF CCL4 CHEMOKINE DRIVES GLIOBLASTOMA TUMOR MICROENVIRONMENT REPROGRAMMING FOLLOWING TREATMENT WITH A NOVEL MRNA VACCINE A Chauhan, G Ebrahim, F Dastmalchi, K McGrath, N Thomas, GP Takacs, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| 987 Glioma-derived factors induce an immune suppressive phenotype in bone marrow-derived CCR2+ myeloid cells G Takacs, J Garcia, A Sherman, C Kreiger, D Luo, J Harrison Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| IMMU-21. GLIOMA-DERIVED FACTORS RECRUIT AND INDUCE AN IMMUNE SUPPRESSIVE PHENOTYPE IN BONE MARROW-DERIVED CCR2+ MYELOID … G Takacs, C Kreiger, D Luo, G Tian, L Deleyrolle, J Harrison Neuro-Oncology 24 (Supplement_7), vii135-vii136, 2022 | | 2022 |
| A CTS Team Approach to Modeling Migration and Suppression of CCR2+/CX3CR1+ Myeloid Cells in Glioblastoma H Anderson, GP Takacs, C Kreiger, D Luo, L Rong, JK Harrison, ... | | 2022 |
| IMMU-05. CCR2+ MYELOID-DERIVED SUPPRESSOR CELLS FROM MURINE GLIOMAS ARE SOURCED FROM THE BONE MARROW, SUPPRESS T CELL … G Takacs, C Kreiger, D Luo, J Flores-Toro, L Deleyrolle, M Rahman, ... Neuro-Oncology 23 (Supplement_6), vi92-vi93, 2021 | | 2021 |
| 84357 A TL1 Team Approach to Integrating Mathematical and Biological Models to Target Myeloid-Derived Immune Cells in Glioblastoma GP Takacs, H Anderson, C Kreiger, D Luo, L Rong, T Stepien, ... Journal of Clinical and Translational Science 5 (s1), 20-20, 2021 | | 2021 |
